Richard I. Steinhart Joins Atossa Genetics' Board of Directors

Richard I. Steinhart Joins Atossa Genetics' Board of Directors  SEATTLE, WA -- (Marketwired) -- 03/03/14 --   Atossa Genetics Inc. (NASDAQ: ATOS), announced today that Richard I. Steinhart has joined the Company's Board of Directors and has been appointed a Member of the Audit Committee and Compensation Committee.  "Richard Steinhart brings a wealth of experience addressing the business needs of development stage, technology driven companies, including device and pharmaceutical companies," said Dr. Steven Quay, Chairman, President and CEO. "His expertise will add great value to Atossa's Board of Directors and the Audit and Compensation Committees. I'm confident that Richard's contributions will be invaluable as we continue to advance our product pipeline."  Mr. Steinhart has had a successful career on Wall Street and is a veteran of the life sciences industry. From 2006 through 2013, he was an executive at MELA Sciences, most recently serving as its CFO and Senior Vice President. From1992 to 2006, Mr. Steinhart was a Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and CFO at Emisphere Technologies from 1991 to 1992 and as General Partner and CFO of CW Group Inc. Mr. Steinhart is currently a Member of the Board of Directors of Actinium Pharmaceuticals, Chairman of its Audit Committee and a member of the Compensation Committee. From 2004 to 2012, Mr. Steinhart was a Member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee. Mr. Steinhart is a Certified Public Accountant (inactive) in New York State and holds a MBA with Honors from Pace University.  "Atossa Genetics brings unique assets and capabilities that I believe will play a very important role in improving women's health over the coming years," commented Mr. Steinhart. "I am excited about joining Atossa's Board of Directors and look forward to working closely with management and the Board to realize the full potential of this important technology."  About Atossa Genetics  Atossa Genetics Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., the offering of laboratory services and tests. For additional information, please visit www.atossagenetics.com.   Forward-Looking Statements  Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including timing of review by the FDA of 510(k) submissions, and actions related thereto, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.  Contact:  Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 800-351-3902 Kyle.Guse@atossagenetics.com   MBS Value Partners Matthew D. Haines (Investors and Media) Managing Director (O) 212-710-9686 Matt.Haines@mbsvalue.com